SCHEMBL23906116

SCHEMBL23906116

Cc1cc(-c2c(C(C)C)nc(Oc3ccc(C(=O)O)cc3)c3cc(N)c(C=N)cc23)ccn1

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RXRA P19793 1/20 0.38
NR4A2 P43354 1/20 0.38
PDE10A Q9Y233 6/20 0.34
LCK P06239 1/20 0.34
KDR P35968 1/20 0.34
TEK Q02763 1/20 0.34
LOXL2 Q9Y4K0 1/20 0.32
HAO1 Q9UJM8 1/20 0.32
TNK2 Q07912 1/20 0.31
PIN1 Q13526 1/20 0.31
ROCK2 O75116 1/20 0.31
ROCK1 Q13464 1/20 0.31
PTGER4 P35408 2/20 0.30
PSEN1 P49768 1/20 0.30
PSEN2 P49810 1/20 0.30
APH1B Q8WW43 1/20 0.30
NCSTN Q92542 1/20 0.30
APH1A Q96BI3 1/20 0.30
PSENEN Q9NZ42 1/20 0.30
PORCN Q9H237 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23896376 0.82 RXRA (0.41) RXRANR4A2PDE10ALOXL2HAO1
SCHEMBL23906193 0.82 MAP4K4 (0.34) ADORA2A
SCHEMBL30252022 0.80 PDE10A (0.39) RXRANR4A2PDE10AHAO1ROCK1
SCHEMBL23906122 0.80 PDE10A (0.39) RXRANR4A2PDE10AHAO1ROCK1
SCHEMBL25544736 0.70 RXRA (0.43) RXRANR4A2PTGER4
SCHEMBL23888012 0.69 RXRA (0.42) RXRANR4A2PTGER4
SCHEMBL23906133 0.69 RXRA (0.43) RXRANR4A2PIN1PTGER4
SCHEMBL23905518 0.68 CHEK2 (0.38) PIN1PTGER4
SCHEMBL23906056 0.65 GCGR (0.41)
SCHEMBL23905458 0.64 PTGER4 (0.41) RXRANR4A2HAO1ROCK1PTGER4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2021203025-A1 1 H-PYRAZOLO[4,3-G]ISOQUINOLINE AND 1 H-PYRAZOLO[4,3-G]QUINOLINE DERIVATIVES AS ALPHA-1 -ANTITRYPSIN MODULATORS FOR TREATING ALPHA-1 -ANTITRYPSIN DEFICIENCY (AATD) VERTEX PHARMACEUTICALS INCORPORATED (US) 2021-10-07 WO disclosed